NBI-1076986 is under clinical development by and currently in Phase I for Movement Disorders. According to GlobalData, Phase I drugs for Movement Disorders have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NBI-1076986’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBI-1076986 overview
NBI-1076986 is under development for the treatment of movement disorders. It is administered through oral. The drug candidate acts by targeting muscarinic 4 receptor.
Neurocrine Biosciences overview
(Neurocrine) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. The company鈥檚 lead product Ingrezza, is a vesicular monoamine transporter 2 (VMAT2) inhibitor to treat adults with tardive dyskinesia and chorea associated with Huntington鈥檚 disease. It is developing a pipeline of drug candidates for various indications in neurology, neuroendocrinology, and neuropsychiatry. Neurocrine also conducts clinical trials and studies for diseases such as movement disorders, epilepsy, and congenital adrenal hyperplasia, among others. The company works in collaboration with and for products distribution. Neurocrine is headquartered in San Diego, California, the US.
For a complete picture of NBI-1076986’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
